On February 28, the ChiHeal Bio , Taikang Xianlin Gulou Hospital, and Shijiazhuang Diskeyway held the "Strategic Cooperation Signing Ceremony and Academic Seminar" at the Taikang Xianlin Gulou Hospital Phase II. The three parties engaged in deep cooperation, marking not only an academic feast that blends traditional Chinese and Western medicine but also an innovative practice of integrating industry, academia, and research.

The event was attended by Zou Xiaoping, Dean of Taikang Xianlin Gulou Hospital, Dr. Zhang Zhefeng, Chairman of ChiHeal Bio, and several experts in the field of Traditional Chinese Medicine. The event was hosted by Wang Xi, Vice Dean of Taikang Xianlin Gulou Hospital.

In his speech, Zou Xiaoping, Dean of Taikang Xianlin Gulou Hospital, highlighted that clinical observations have shown a significant increase in cases of pulmonary nodules following COVID-19, and that Traditional Chinese Medicine (TCM) could play a crucial role in addressing this issue. To transform traditional Chinese medicinal formulas into hospital preparations, Taikang Xianlin Gulou Hospital will engage in deep collaboration with ChiHeal Bio Nanjing, Shijiazhuang Diskeyway, and Dr. Wang Ning, with the goal of benefiting more patients with pulmonary nodules, advancing the modernization and standardization of TCM, and contributing to the collaborative development of medical education, research, and treatment at the hospital.

In his speech, Dr. Zhang Zhefeng, Chairman of ChiHeal Bio, stated that Traditional Chinese Medicine (TCM) hospital preparations have become a new opportunity in the pharmaceutical industry. He noted that the scientific achievements of hospital experts and scientists are often difficult to apply widely. However, if these results are developed into hospital preparations or innovative TCM drugs, it can expand the scope of benefits for patients. He expressed hope that the three parties would work together to establish the “Anti-Pulmonary Nodule TCM Preparation” as a benchmark product in the field of Traditional Chinese Medicine.

Subsequently, Vice Dean Bai Feng of Taikang Xianlin Gulou Hospital, Ms. Hou Wen, Vice General Manager of ChiHeal Bio, and Professor Wang Ning, a Traditional Chinese Medicine expert, signed the strategic cooperation agreement.

Professor Wang Ning delivered a special report titled "Introduction to Anti-Pulmonary Nodule TCM Hospital Preparations." He emphasized that pulmonary nodules have become a significant health threat to the Chinese population. Combining Traditional Chinese Medicine (TCM) theories for treating pure ground-glass pulmonary nodules, he elaborated on the clinical efficacy and development prospects of the formula. Through clinical practice, the formula has shown ideal results in improving symptoms and enhancing the quality of life for patients with pulmonary nodules.

The academic seminar officially kicked off with Xia Qin, Director of the Pharmacy Department at Nanjing Chinese Medicine Hospital, delivering a report titled "Current Research Status and Development of Hospital TCM Preparations." In his presentation, he thoroughly analyzed the current trends and challenges in the development of hospital TCM preparations, providing valuable insights for the attendees. Professor Wang Yingfeng then presented on "Research and Development Ideas and Processes for Innovative TCM Drugs," sharing his experience and insights into the R&D of innovative TCM drugs.

In his concluding remarks, Wang Xi, Vice Dean of Taikang Xianlin Gulou Hospital, stated that the successful signing ceremony and academic seminar not only marked a new milestone in the three parties' cooperation in the field of TCM preparations but also provided a new opportunity for the hospital to advance TCM preparation R&D and enhance its innovation and service capabilities. He expressed anticipation for the close collaboration between the hospital and pharmaceutical companies, believing that this partnership would lead to the development of TCM formulas beneficial to patients.

Traditional Chinese Medicine (TCM) is a treasure of the Chinese nation, with a history spanning thousands of years and remaining ever-relevant. As a CRO enterprise focused on TCM research and development, the Nanjing ChiHeal Bio TCM team at Diskeyway has always adhered to the mission of "Upholding Tradition, Innovating with Technology," committed to integrating traditional TCM wisdom with modern scientific research to promote the standardization, modernization, and internationalization of TCM development.

The strategic cooperation with Gulou Hospital marks an important milestone in fulfilling our mission. It also represents a new beginning of complementary strengths and joint efforts to serve the health of the people. Nanjing ChiHeal Bio will leverage its professional advantages in TCM research and development, guiding efforts with clinical needs, and creating safe, effective, and quality-controlled hospital TCM preparations tailored to patients. Through close collaboration between the two parties, more "clinically inspired, innovation-driven" TCM products will be transformed into powerful tools for clinical treatment, breathing new life into traditional TCM within the modern medical system.

This collaboration is not only a "two-way journey" between research and clinical practice but also a "value co-creation" between industry and healthcare. According to the agreement, the ChiHeal Bio team will be responsible for the R&D, process optimization, and technical support for TCM preparations, while Gulou Hospital, with its strong clinical resources and patient service system, will drive the clinical application and promotion of the hospital preparations. This partnership aims to achieve resource sharing, risk sharing, and mutual success, paving a sustainable and innovative path for the industrialization of Traditional Chinese Medicine.

Hospital preparations are an important vehicle for the inheritance and innovation of Traditional Chinese Medicine (TCM) and a key approach to meeting the personalized treatment needs of patients.  ChiHeal Bio will use this collaboration as an opportunity to strictly adhere to the research and development principles of "Quality First, Efficacy-Based," ensuring that each preparation stands up to scientific scrutiny and clinical testing.